DI Mobile Menu

Search form


Nuclear Imaging

Nuclear Imaging

F-18-flurorothymidine PET appears to be useful in assessing the grade and proliferation in gliomas, especially in newly diagnosed patients.

Dose awareness extends to nuclear medicine exams with the development of online materials to guide providers on radiopharmaceutical dose utilization.

Video: Roberto Soto, MD, discusses using PET imaging with Amyvid for Alzheimer’s evaluation, including reimbursement, training, and benefits of the new test.

Video: Roberto Soto, MD, of Precision Imaging, shows a recent PET imaging case using Amyvid, recently approved for evaluation of Alzheimer's.

Clinicians at Mount Sinai in New York are the first in the state to use a recently FDA-approved PET technique with florbetapir to detect Alzheimer’s disease.

PET imaging has demonstrated an unexpected link between low dopamine levels and aggression in young healthy adults.

New diagnostic agents for use with PET imaging are improving identification of beta-amyloid, the brain plaque associated with Alzheimer’s disease. But there are some concerns about training to accurately read these studies.


Subscribe to Nuclear Imaging on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.